Develops first-in-class TCR-T therapies for common and rare solid tumors using proprietary antigen discovery and memory T cell reprogramming. Integrates generative AI to optimize antigen identification and engineer epigenetically reprogrammed autologous central memory T cells targeting validated immunogenic tumor antigens for durable immunoprotection.